Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Underwritten Public Offering
Summary
Praxis Precision Medicines, Inc. announced on October 16, 2025, an underwritten public offering of 3,025,480 shares of its common stock and pre-funded warrants to purchase up to 318,470 shares of common stock. The offering, with an expected closing date of October 20, 2025, is expected to raise approximately $567.0 million in net proceeds after underwriting discounts, commissions, and estimated offering expenses. The company intends to use the net proceeds for research and development activities, preparation for potential commercialization, advancement of earlier stage assets, and for working capital and other general corporate purposes. The offering was made pursuant to a shelf registration statement previously filed with the SEC.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement